IRCT20190727044343N2CompletedPhase 2
Atorvastatin effect in Clinical and Laboratory findings of patiens with COVID-19 admitted RAZI referral hospital in Mazandaran State: A Randomized Clinical Trial
Mazandaran University of Medical Sceinces0 sites100 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20 years to 50 years (—)
- Sex
- All
Inclusion Criteria
- •Confirmed COVID-19 Diagnosis
- •No prior Cardiovascular Disease
- •No history of Statins use
- •Chloroquine use
- •No prior Kaletra usage
- •No prior liver damage
- •No prior myositis
Exclusion Criteria
- •Prior Kaletra Use
- •Cardiovascular Disease
- •Prior myositis
- •Prior Liver damage
Investigators
Similar Trials
Completed
Phase 3
Effect of Atorvastatin in treatment of COVID-19 infectioIRCT20200413047062N1Islamic Azad University76
Recruiting
Phase 3
The effect of atorvastatin administration on the outcome of patients with traumatic brain injuryIRCT20210113050023N1Ahvaz University of Medical Sciences60
Recruiting
Not Applicable
In- Vivo Bioequivalence study of Atorvastatin tablets 40 mg Kharazmi Pharma with brand drugs (LIPITOR® 40 mg, Pfizer, Germany) in Iranian healthy volunteers.IRCT20200105046010N72Kharazmi Pharmaceutical Co.24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Atorvastatin® tablet with brand drugs (LIPITOR® 100mg, Pfizer, Germany).IRCT20200105046010N33Razak Pharma24
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Atorvastatin® tablet with brand drugs (LIPITOR® 100mg, Pfizer, Germany).IRCT20200105046010N29Zagross Darou Pharmaceutical Company24